These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32366671)

  • 1. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
    Dunphy MPS; Pressl C; Pillarsetty N; Grkovski M; Modi S; Jhaveri K; Norton L; Beattie BJ; Zanzonico PB; Zatorska D; Taldone T; Ochiana SO; Uddin MM; Burnazi EM; Lyashchenko SK; Hudis CA; Bromberg J; Schöder HM; Fox JJ; Zhang H; Chiosis G; Lewis JS; Larson SM
    Clin Cancer Res; 2020 Oct; 26(19):5178-5187. PubMed ID: 32366671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
    Speranza G; Anderson L; Chen AP; Do K; Eugeni M; Weil M; Rubinstein L; Majerova E; Collins J; Horneffer Y; Juwara L; Zlott J; Bishop R; Conley BA; Streicher H; Tomaszewski J; Doroshow JH; Kummar S
    Invest New Drugs; 2018 Apr; 36(2):230-239. PubMed ID: 28808818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring Tumor Epichaperome Expression Using [
    Jhaveri KL; Dos Anjos CH; Taldone T; Wang R; Comen E; Fornier M; Bromberg JF; Ma W; Patil S; Rodina A; Pillarsetty N; Duggan S; Khoshi S; Kadija N; Chiosis G; Dunphy MP; Modi S
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33283132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
    Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
    Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
    Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
    J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
    Gallerne C; Prola A; Lemaire C
    Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
    Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
    Kale Ş; Korcum AF; Dündar E; Erin N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
    Li HK; Matsumoto Y; Furusawa Y; Kamada T
    J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
    Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
    Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
    Usmani SZ; Bona RD; Chiosis G; Li Z
    J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of [
    Vermeulen K; Naus E; Ahamed M; Attili B; Siemons M; Luyten K; Celen S; Schymkowitz J; Rousseau F; Bormans G
    Theranostics; 2019; 9(2):554-572. PubMed ID: 30809293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
    Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
    Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
    Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
    PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.
    Lisi L; McGuire S; Sharp A; Chiosis G; Navarra P; Feinstein DL; Dello Russo C
    J Neuroimmunol; 2013 Feb; 255(1-2):1-7. PubMed ID: 23123171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
    Carter BZ; Mak PY; Muftuoglu M; Tao W; Ke B; Pei J; Bedoy AD; Ostermann LB; Nishida Y; Isgandarova S; Sobieski M; Nguyen N; Powell RT; Martinez-Moczygemba M; Stephan C; Basyal M; Pemmaraju N; Boettcher S; Ebert BL; Shpall EJ; Wallner B; Morgan RA; Karras GI; Moll UM; Andreeff M
    Blood; 2023 Sep; 142(12):1056-1070. PubMed ID: 37339579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of
    Dunphy MPS; Harding JJ; Venneti S; Zhang H; Burnazi EM; Bromberg J; Omuro AM; Hsieh JJ; Mellinghoff IK; Staton K; Pressl C; Beattie BJ; Zanzonico PB; Gerecitano JF; Kelsen DP; Weber W; Lyashchenko SK; Kung HF; Lewis JS
    Radiology; 2018 May; 287(2):667-675. PubMed ID: 29388903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.